# Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients

> **NCT04441424** · NA · COMPLETED · sponsor: **Alkarkh Health Directorate-Baghdad** · enrollment: 49 (actual)

## Conditions studied

- IMMUNOTHERAPY

## Interventions

- **BIOLOGICAL:** Convalescent plasma
- **DRUG:** Hydroxychloroquin with Azithromycin

## Key facts

- **NCT ID:** NCT04441424
- **Lead sponsor:** Alkarkh Health Directorate-Baghdad
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-03
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04441424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04441424, "Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04441424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*